Inaedis, Inc.

Startup

Inaedis, Inc. is a spin out from Princeton University revolutionizing vaccine formulation and delivery with its Rapid Room-Temperature Aerosol Dehydration (RTAD) technology, addressing critical challenges in vaccine stability, distribution, efficacy, and dosage. RTAD enables the production of shelf-stable, bioactive vaccine powders and facilitates the creation of ultra-high concentration protein suspensions, potentially enabling smaller injection volumes or higher antigen doses for enhanced immune response.

Key Benefits for Vaccines:

- Thermostability: RTAD preserves vaccine integrity at room temperature, ensuring potent doses even in regions with limited refrigeration.

- Versatility: Compatible with diverse vaccine types, including viral vectors, mRNA-LNPs, and subunit vaccines.

- Concentration: Enables high concentration formulations, leading to smaller dose volumes or the ability to deliver multiple antigens in a single injection.

- Improved Access: Simplifies distribution to remote and underserved populations, enhancing global immunization efforts.

- Enhanced Delivery: RTAD-produced powders can be formulated for various delivery methods, including nebulizers for inhalation and microneedle patches for transdermal administration, potentially improving patient compliance.

Inaedis’ innovative RTAD technology can help to transform vaccine development and delivery strategies, ensuring safer, more accessible, more effective, and more dose-efficient immunization programs worldwide.